Epidemiology and Surveillance, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, 3720BA Bilthoven, The Netherlands.
Vaccine. 2013 Sep 23;31(41):4541-7. doi: 10.1016/j.vaccine.2013.07.060. Epub 2013 Aug 6.
Pertussis has resurged in the Netherlands since 1996. Several measures, i.e. acceleration of the schedule, introduction of a preschool acellular pertussis booster and change from an infant whole cell to an acellular pertussis combination vaccine were implemented in the National Immunisation Programme to decrease disease burden, in particular among very young infants who have the highest morbidity and mortality of pertussis. Nevertheless, a large outbreak occurred in 2011-2012.
1996-2010 was divided in 3-year-periods to assess the impact of the measures taken, using notifications and hospitalisations. These results were compared with 2011-2012. Mean Incidence rates (IRs) per 100,000 were calculated.
Although the measures taken resulted in decreased IRs among the targeted age groups after implementation, overall mean IRs of notifications increased from 32 (1996-2004) to 37 (2005-2010) and 63 (2011-2012). Young infants, not yet vaccinated, did not benefit; during the 2011-2012 outbreak, IR in 0-2-month-olds amounted to 259.6. IR among persons over 9 years of age increased from 6.8 (1996-1999) to 59.1 (2011-2012) For hospitalisations overall mean IRs decreased from 1.95 per 100,000 (1997-2004) to 0.88 (2005-2010) and 0.76 (2011).
The measures taken reduced IRs of notifications and hospitalisations among groups eligible for vaccination, but had no effect on the increasing IRs in adolescents and adults. This trend is also observed in other countries. The high IRs in 2012 in adolescents and adults probably resulted in increased transmission to infants, who are at risk for contracting severe pertussis. Therefore, additional measures to protect this group should be considered.
自 1996 年以来,荷兰百日咳卷土重来。为了降低疾病负担,特别是降低发病率和死亡率最高的婴幼儿百日咳发病率,国家免疫计划采取了一些措施,如加快接种进度、在学前阶段接种非细胞性百日咳加强针、用非细胞性百日咳结合疫苗替代全细胞性百日咳婴儿疫苗。然而,2011-2012 年仍出现了大规模暴发。
将 1996-2010 年分为 3 年时间段,通过通知和住院数据评估所采取措施的效果。将这些结果与 2011-2012 年进行比较。每 10 万人的平均发病率(IR)进行计算。
尽管实施这些措施后目标年龄段的发病率有所下降,但总体通知的平均发病率从 32(1996-2004 年)增加到 37(2005-2010 年)和 63(2011-2012 年)。尚未接种疫苗的婴幼儿并未从中受益;在 2011-2012 年暴发期间,0-2 月龄婴儿的发病率为 259.6。9 岁以上人群的发病率从 6.8(1996-1999 年)增加到 59.1(2011-2012 年)。住院的总体平均发病率从每 10 万人 1.95 例(1997-2004 年)下降到 0.88(2005-2010 年)和 0.76(2011 年)。
所采取的措施降低了符合接种条件人群的通知发病率和住院率,但对青少年和成年人发病率的上升没有影响。其他国家也观察到了这种趋势。2012 年青少年和成年人发病率较高,可能导致婴幼儿感染率增加,婴幼儿患严重百日咳的风险增加。因此,应考虑采取额外措施保护这一人群。